Q2 2026 Zevra Therapeutics Inc Earnings Call Transcript
Key Points
- Zevra Therapeutics Inc (ZVRA) reported a 53% year-over-year increase in total net revenue for Q2 2026, reaching $39.7 million, driven by strong US sales of MIPLYFFA.
- The company strengthened its intellectual property position for MIPLYFFA with an Orange Book listing providing protection through 2041, supporting long-term commercial opportunity.
- Zevra Therapeutics Inc (ZVRA) maintains a robust financial foundation with over $260 million in cash, cash equivalents, and investments, providing flexibility for strategic investments.
- The company's commercial strategy is showing progress, with 184 prescription enrollment forms for MIPLYFFA received since launch, including a diverse mix of newly diagnosed, previously diagnosed, adult, and pediatric patients.
- Zevra Therapeutics Inc (ZVRA) continues to advance its pipeline, including the Phase III DISCOVER trial for celiprolol, and is exploring regulatory pathways to accelerate development.
- The company achieved net income of $8.8 million in Q2 2026, demonstrating improved profitability compared to the prior year period.
- Zevra Therapeutics Inc (ZVRA) is expanding access to MIPLYFFA through global expanded access programs in response to strong international interest.
- The CHMP issued a negative opinion regarding the arimoclomol Marketing Authorization Application in the EU, creating regulatory uncertainty for the product's approval in Europe.
- Reimbursements beyond the French EAP for arimoclomol are expected to be highly variable and unpredictable in the near term, impacting revenue stability.
- The company incurred a $6.4 million non-cash mark-to-market charge related to outstanding common stock warrants, which negatively impacted reported net income.
- The celiprolol Phase III DISCOVER trial is progressing slowly, with only 3 confirmed events out of the 28 required to trigger the interim analysis, indicating a lengthy timeline.
- Zevra Therapeutics Inc (ZVRA) faces ongoing challenges in patient identification and diagnosis for NPC, with an estimated 300-350 diagnosed patients out of a potential 900, limiting near-term market growth.
- The company's reliance on a single commercial product, MIPLYFFA, for US revenue growth exposes it to concentration risk.
- The re-examination process for arimoclomol with the CHMP is expected to take approximately 120 days, with the outcome uncertain and potentially unfavorable.
Afternoon. Thank you for joining Zevraâs second quarter 2026 financial results and corporate update conference call. Todayâs call is being recorded and will be available via the investor relations section of the companyâs website later today.
The host for todayâs call is Nichol Ochsner, Zevraâs Vice President of Investor Relations and Corporate Communications.
Thank you. Welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our second quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website.
Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
